Literature DB >> 16775247

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.

Federico Cappuzzo, Lynne Bemis, Marileila Varella-Garcia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16775247     DOI： 10.1056/NEJMc060020

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  67 in total

1.  p95HER2 truncated form in resected non-small cell lung cancer.

Authors:  Federico Cappuzzo; Yong Gon Cho; Andrea Sacconi; Greta Alì; Olimpia Siclari; Matteo Incarbone; Annarita Destro; Luigi Terracciano; Gabriella Fontanini; Antonio Marchetti; Massimo Roncalli; Marileila Varella-Garcia
Journal:  J Thorac Oncol       Date:  2012-03       Impact factor: 15.609

2.  Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Authors:  Ogechi N Ikediobi; Helen Davies; Graham Bignell; Sarah Edkins; Claire Stevens; Sarah O'Meara; Thomas Santarius; Tim Avis; Syd Barthorpe; Lisa Brackenbury; Gemma Buck; Adam Butler; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kristian Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jonathan Hinton; Chris Hunter; Andy Jenkinson; David Jones; Vivienne Kosmidou; Richard Lugg; Andrew Menzies; Tatiana Mironenko; Adrian Parker; Janet Perry; Keiran Raine; David Richardson; Rebecca Shepherd; Alex Small; Raffaella Smith; Helen Solomon; Philip Stephens; Jon Teague; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; William Reinhold; John N Weinstein; Michael R Stratton; P Andrew Futreal; Richard Wooster
Journal:  Mol Cancer Ther       Date:  2006-11-06       Impact factor: 6.261

3.  Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.

Authors:  Ronan J Kelly; Corey Carter; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

Review 4.  Surgery for NSCLC in the era of personalized medicine.

Authors:  Tetsuya Mitsudomi; Kenichi Suda; Yasushi Yatabe
Journal:  Nat Rev Clin Oncol       Date:  2013-02-26       Impact factor: 66.675

Review 5.  Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.

Authors:  Janakiraman Subramanian; Archana Katta; Ashiq Masood; Dashavantha Reddy Vudem; Rama Krishna Kancha
Journal:  Oncologist       Date:  2019-07-10

Review 6.  New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).

Authors:  Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

7.  Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.

Authors:  Gerald S Falchook; Filip Janku; Anne S Tsao; Christel C Bastida; David J Stewart; Razelle Kurzrock
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

8.  Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

Authors:  Juliann Chmielecki; Jeffrey S Ross; Kai Wang; Garrett M Frampton; Gary A Palmer; Siraj M Ali; Norma Palma; Deborah Morosini; Vincent A Miller; Roman Yelensky; Doron Lipson; Philip J Stephens
Journal:  Oncologist       Date:  2014-12-05

9.  Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.

Authors:  Juliana Eng; Meier Hsu; Jamie E Chaft; Mark G Kris; Maria E Arcila; Bob T Li
Journal:  Lung Cancer       Date:  2016-05-31       Impact factor: 5.705

10.  Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.

Authors:  Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Javier A Menendez
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.